Ahmedabad, Gujarat, India, February 2026 – Intas Pharmaceuticals has announced the appointment of Sunil Baluni as General Manager – Intas Women Healthcare, strengthening its leadership in the women’s healthcare segment.
With over 25 years of experience across Gynaecology, IUI, and IVF therapy areas, Sunil has built a distinguished career driving business growth, profitability, and operational excellence. He brings deep expertise in leading sales and marketing functions, managing P&L responsibilities, executing successful product launches, and building high-performing teams that deliver sustained market impact.
Prior to joining Intas, Sunil spent over 12 years at Bharat Serums and Vaccines Limited (BSV), where he most recently served as National Sales Manager. In this role, he led revenue and profit strategy for the business unit, strengthened sales force effectiveness, developed customized marketing plans, and built strong stakeholder relationships across the ecosystem. His tenure at BSV also included leadership roles as Zonal Business Manager for North India and Divisional Sales Manager, where he managed large cross-regional teams across North and East India in Gynecology, IUI, and IVF therapy areas.
Throughout his career, Sunil has demonstrated strong strategic orientation, commercial acumen, and the ability to cultivate collaborative cultures that enhance both business performance and patient outcomes. His experience in leading large teams and navigating competitive therapy segments positions him well to further strengthen Intas Women Healthcare.
Sunil holds a Master’s degree in Physics from S.G.R.R. (P.G.) College, Garhwal University, Dehradun, adding a strong analytical foundation to his leadership profile.
About Intas Pharmaceuticals
Intas Pharmaceuticals is a leading multinational pharmaceutical formulation development, manufacturing, and marketing organization, present in over 85 countries. The company has crossed the $2.5 billion revenue mark and continues to grow at a strong CAGR. Ranked 6th in the Indian pharmaceutical market, Intas is the largest privately owned Indian generic pharma company and among the top 10 generic players in highly regulated markets such as the EU, US, and UK.
With 17 advanced formulations, R&D, and distribution facilities worldwide and over 23,000 employees, Intas invests approximately 6–7% of its revenues in R&D and maintains more than 10,000 product registrations globally.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
